-
Large study on milk: Risky for women but not for men
The risk of ischemic heart disease (IHD) and acute myocardial infarction (MI) increased for women with milk intake levels higher than 2 glasses per day, while no such association was found in men, according to a new large Swedish study.
-
In search of Marcel Proust's lost health
A great writer, but also a weak person and a hypochondriac. That has been the usual image of Marcel Proust. But the pediatrician and literary scholar Carl Lindgren paints a partly different picture in a new book about the French master's life, health and attitude towards physicians.
-
Q-linea tar in kapital till fortsatt USA-satsning – ”Har positionerat oss starkt”
Uppsalabolaget Q-linea, som utvecklar produkter för infektionsdiagnostik, har beslutat att ta in upp till 225 miljoner kronor i en nyemission.
-
Anna Törner: The clinical trial – Periscope to reality
What happens to the patients in the clinical trial is not very interesting, writes Anna Törner in a column.
-
Founder of Bioarctic, Lars Lannfelt, is honoured: “I want to create something for the future”
It´s like a scientist’s dream: to be the world’s first with a drug that genuinely affects one of our major diseases. Lars Lannfelt and his company Bioarctic have achieved just that, and they are thus making a significant contribution to the history of Swedish medicine. He is now being awarded the Research!Sweden Award 2023.
-
Samuel Lagercrantz: A special kind of hellishness afflicts post-COVID patients
In addition to the disease itself those suffering from post-COVID have to deal with people who try to label them as hypochondriacs, writes Samuel Lagercrantz in an editorial.
-
Xbrane tar in 350 miljoner för fortsatt utveckling och uppskalning
Solnabaserade biosimilarbolaget Xbrane Biopharma tar in totalt 350 miljoner kronor genom dels en riktad nyemission, dels en finansiering via konvertibla obligationer.
-
Samuel Lagercrantz: The government’s performance in healthcare and life sciences so far
Since the change of government in Sweden, developments in the healthcare sector have shown promising signs, but the outlook in life sciences is less promising, writes Samuel Lagercrantz in an editorial.
-
Column: ”Authentic leadership and clear mandates pave the way for more female CEOs”
”I believe that the aspect of having clear mandates and titles on the one hand and women progressing into top positions must be explored further”, Helena Strigård writes in a column.
-
Biosimilars bring price pressure, but are they sufficiently used?
When biosimilars were introduced just over 16 years ago, hopes were raised that they would give many more patients access to effective but otherwise extremely expensive treatments with biological drugs. So, how well has Swedish healthcare used biosimilars? The answer partly depends on whom you ask.
-
Investments worth 40 billion in the Öresund region – “A huge investment wave”
A new report reveals that medical companies in the Oresund region are investing like never before.
-
Marie Gårdmark: Big data evidence generation drives change in the EU regulatory system
Rapid developments in technology have led to the possibility for the generation and analysis of vast volumes of data. Will the availability of big data lead to fundamental changes to the regulatory system? In a column Marie Gårdmark, CEO and Senior Consultant at RegSmart Life Science, develops her views on this subject.
-
Miljontals munskydd stoppades i tullen
Tullverket stoppade i fjol nästan sju miljoner munskydd och andra sjukvårdsprodukter som bedömdes som osäkra – en gigantisk ökning jämfört med året innan.
-
Upcoming event: New updates on drugs
At Medicon Valley Alliance venues in Copenhagen/Örestad April 1 2020 the meeting New updates in Drug Formulation & Bioavailability takes place for the for the eighth time.
-
Femte förslaget till regeringen från SwedenBio
Skärp målsättningen för deltagandet i EU:s ramprogram. Det är SwedenBios femte förslag inför den kommande forskningspropositionen.
-
Hon får Scheelepriset
Professor Emmanuelle Charpentier tilldelas 2019 års Scheelepris. Hon har spelat en avgörande roll i upptäckten av gensaxen Crispr-Cas9.
-
"Det var inget lätt beslut att fatta"
Två av Recipharms svenska anläggningar läggs ner och 225 anställda berörs av beslutet. Här berättar bolagets vd.
-
Cellatlasen publicerar unika resultat i Science
Human protein atlas-projektet publicerar nu den första övergripande kartan över var proteinerna befinner sig i cellen. Artikeln återfinns i Science.
-
Många projekt i klinisk fas
Antalet projekt i klinisk utveckling hos svenska läkemedelsbolag nådde under det gångna året toppnoteringen 144. Det meddelar Sweden Bio i årets pipeline-rapport.
-
Minskad vinst för Sectra
Vill expandera inom Imaging IT Solutions och nå nya marknader.
-
Finansierar karriärlyft
För att bidra till ökad internationell erfarenhet får ytterligare 17 forskare nu pengar från Vinnovas program Mobility for Growth.
-
Han leder nya Umeåcentret
Professor Tommy Olsson är ny föreståndare för Wallenberg centrum för molekylärmedicinsk forskning vid Umeå universitet.
-
Tappar i värde
Värdet på Karolinska Developments portfölj har minskat med 225 miljoner kronor men bolaget fortsätter med sin nya strategi.
-
KAW ger 175 miljoner till Umeåcenter
16 unga forskare rekryteras till ett nytt centrum för molekylärmedicin i Umeå.